Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any issues are welcome. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
AusperBio Attended the Annual Meeting of the European Association for the Study of the Liver (EASL™) Held in Amsterdam, Netherlands from May 7 to May 10, 2025. At this conference, AusperBioFormat of Breakthrough PosterPublicationEnd-of-Treatment (EOT) Data from the Phase IIb Clinical Trial of AHB-137 Conducted in China
AHB-137 is aASO drugs under research, used to treat chronic hepatitis B and achieve clinical cure. This report focuses on the interim data from the multi-center, randomized Phase IIb clinical trial of AHB-137, which evaluates AHB-137 in patients receiving nucleos(t)ide analog (NA) therapy.Efficacy and Safety in HBeAg-Negative Chronic Hepatitis B Patients.
[Report Number] LBP-014
【Report Title】Significant HBsAg Clearance and Surface Antibody Seropositivity Achieved in HBeAg-Negative Chronic Hepatitis B Patients Receiving AHB-137 for 16 or 24 Weeks After NA Therapy: Interim Data Report of a Multicenter, Randomized Phase IIb Clinical Study
[Report Period] May 7, 2025 to May 10, 2025
【Report Author】Yanhang Gao, Xieer Liang, Youwen Tan, Haibing Gao, Dachuan Cai, Jidong Jia, Xinrui Wang, Zhihong Liu, Xingbei Zhou, Huaxi Ma, Shan Zhong, Hong Ma, Di Zhao, Chen Yang, Hao Wang, Miao Wang, Cheng Yong Yang, Guofeng Cheng, Jinlin Hou, Junqi Niu
In the study, participants were randomly assigned to the AHB-137 300 mg 24-week treatment group or the 16-week treatment group. The primary endpoints of the study were the levels of hepatitis B surface antigen (HBsAg) below the lower limit of quantification (<0.05 IU/mL) and hepatitis B virus (HBV) DNA levels below the lower limit of quantification (<10 IU/mL) at the end of the treatment period.In the 24-week treatment group, 75% (24/32) of the subjects reached this primary endpoint; in the 16-week treatment group, 66% (21/32) of the subjects reached this primary endpoint.Among the subjects who reached the primary endpoint, more than80% of the subjectsAchieved HBsAg clearance within 12 weeks of treatment, and at the end of treatment,At week 24 and week 16, seroconversion of hepatitis B surface antibody (anti-HBs) was observed in 54% and 33% of participants, respectively.AHB-137 demonstrated good tolerability and effective safety in both treatment groups.Dr. Guozheng Cheng, Co-founder and CEO of AusperBio, stated：“AHB-137 demonstrated exciting efficacy data and favorable safety data in the Phase IIb clinical trial, further confirming the excellent clinical outcomes observed in the Phase IIa trial. This highlights AHB-137's strong potential to become a cornerstone therapy for achieving functional cure in hepatitis B.Dr. Chengyong Yang, Co-founder and CSO of AusperBio, added:"Achieved during the AHB-137 treatment processThe rapid decline in HBsAg and the higher seroconversion rate of hepatitis B surface antibodies are very encouraging. Here, we sincerely thank all the principal investigators, clinical staff, study participants, and the tremendous efforts of every member of our AusperBio team.”As one of the most influential academic conferences in the global liver disease field, the European Association for the Study of the Liver (EASL™) Annual Meeting continues to lead the forefront of clinical innovation and practice transformation. At this conference, AusperBio engaged in in-depth discussions with top experts and scholars worldwide, jointly exploring cutting-edge innovations in hepatitis B clinical cure, and contributing significant efforts to promote global liver health.
Source: AusperBio
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)